Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.

Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. Tumori. 2019 May 16;:300891619851376 Authors: Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, Guglielmi G, Storto G Abstract Radium-223 dichloride (223Ra) is the first, recently approved, α-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on 223Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. 223Ra represents the only bone-targeting agent that has significantly extended patients' overall survival while reducing pain and symptomatic skeletal events. Unlike other radiopharmaceuticals, such as strontium-89 and samarium-153 EDTMP, 223Ra (11.4-days half-life) has shown a high biological efficiency mainly due to its short penetration range. These features potentially allow reduced bone marrow toxicity and limit undue exposure. 223Ra has been validated under the product name Xofigo® by the US Food and Drug Administration and the European Medicines Agency. Patient selection, management, and treatment sequencing is recommended to be discussed in the context of a multidisciplinary environment, including oncology, urology, nuclear medicine, and radiation the...
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research

Related Links:

ConclusionsRadium-223 was generally well tolerated and there were no safety concerns. The adverseevents were mild and manageable. A decline in serum alkaline phosphatase was more frequent than a decline in the prostate-specific antigen. Monitoring changes in serum alkaline phosphatase dynamics may be useful.ResumenEl dicloruro de Ra223 es un radiofármaco emisor alfa que prolonga la supervivencia global en pacientes con cáncer de próstata resistente a la castración y metástasis óseas sintomáticas. Presentamos un análisis retrospectivo de 68 pacientes tratados.Mé...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
ConclusionsThere was no difference in the patient ’s QOL, except that CAB group was associated with significantly better pain relief than LHRH agonist monotherapy at 3 months following ADT, which was not sustained thereafter. Our results suggest that the benefit of prolonged (≥ 3 months) CAB is questionable in terms of patients’ QOL.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
We present the case of a 56 year old male who presented with diffusely worsening back pain along with scrotal swelling who was ultimately diagnosed with metastatic prostate cancer to the bilateral testicles.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 20 May 2019Source: Respiratory Medicine Case ReportsAuthor(s): Yukihisa Hatakeyama, Sho Yoshimura, Taira Ninomaru, Shodai Fujimoto, Rei Takamiya, Kayoko Okamura, Nobuya Sano, Hisashi OhnishiAbstractA 78-year-old Japanese man who had undergone total prostatectomy for prostate cancer (pT3cN1M0, Gleason score 3 + 3) 20 years previously was referred to the Respiratory Medicine Department of our institution because of a 1-week history of chest pain and cough. Computed tomography showed multiple small nodules and mediastinal lymph node enlargement. Bronchoscopy revealed multiple soft ...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Conclusions: Less than half of the patients in this study completed the full series of 6 injections, with patient death being the leading cause for premature termination of treatment. Furthermore, half the patients that died during treatment received 2 injections or less. These findings suggests that referrals for this treatment may be coming too late in the course of the patient’s disease course. Rising PSA levels was the second most common cause for treatment discontinuation. In patients who had both PSA and ALP levels monitored during treatment, PSA remained stable or increased in 83% of the patients who completed...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Technologist Student Papers I Source Type: research
Conclusions: TANDEM-PLRT, concomitantly administering Ac-225 and Lu-177 PSMA-617, seems to be feasible, safe and effective in end-stage metastatic prostate cancer, refractory to Lu-177 PSMA. The administered radioactivity of Ac-225 PSMA can be lowered and the risk of dose-limiting toxicity (xerostomia, xerophthalmia etc.) be minimized. There might be a potential synergistic effect using two radionuclides with different emission characteristics.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Therapy I Source Type: research
Conclusions: We concluded that Lu177 PSMA therapy has adequate pain palliation in all end-stage mCRPC patients and it has the potential to become an effective therapeutic option in properly selected patients. Keywords: Lu177 PSMA, Safety, efficacy, mCRPC, Low-performance status
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Therapy I Source Type: research
Conclusions: Our findings show that 177Lu-PSMA-I&T therapy has early promising response rates and low toxicity in men with mCRPC who have progressed after conventional treatments in our local setting.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Therapy II Source Type: research
Publication date: Available online 18 May 2019Source: Journal of Herbal MedicineAuthor(s): Richard Komakech, Youngmin KangAbstractMedicinal plants have been an integral part of the healthcare system for centuries. Prunus africana, an evergreen plant of the family Rosaceae in sub-Saharan Africa, has been used to treat numerous diseases and disorders since time immemorial. Over the past decades, several ethnomedicinal surveys were conducted in many communities across Africa which validated the use of P. africana in traditional medicine. The increased interest in P. africana across the globe has led to several pharmacological...
Source: Journal of Herbal Medicine - Category: Complementary Medicine Source Type: research
AbstractPurpose of ReviewTo summarize recent investigation into associations between the genitourinary microbiota and prostatic disease.Recent FindingsThe genitourinary tract is not sterile. There are microbial communities (microbiota) in each niche of the genitourinary tract including the bladder, prostate, and urethra, which have been the subject of increasing scientific interest. Investigators have utilized several unique methods to study them, resulting in a highly heterogeneous body of literature. To characterize these genitourinary microbiota, diverse clinical specimens have been analyzed, including urine obtained by...
Source: Current Urology Reports - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Environmental Health | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Nuclear Medicine | Pain | Pain Management | Politics | Prostate Cancer | Radiation Therapy | Reclast | Toxicology | Urology & Nephrology | Websites | Zometa